Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis.
Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis.
复制标题
DOI：
10.1007/s10067-015-2949-3
复制
发表时间：
2015-06
影响因子：
3.4
通讯作者：
Reveille, John D.
中科院分区：
文献类型：
--
作者：
Reveille, John D.
随着人们对慢性背痛和中轴性脊柱关节炎的影响的认识不断提高，以及遗传学方面的最新突破和可能对早期疾病产生最佳影响的新型治疗方法的发展，对标记物的需求从未如此之大，这些标记物可以促进早期诊断和分析那些处于不良结局最高风险的个体。强直性脊柱炎的遗传基础已经相当先进，HLA-B27检测在诊断中发挥作用。对疾病易感性的遗传贡献的其余部分的知识仍然不完整，并且使用广泛的基因检测（除了HLA-B27）进行诊断可能还为时过早。血清和血浆生物标志物在评估疾病活动性、治疗反应以及作为预测因子或放射学严重程度方面已被广泛检查。对于评估疾病活动性，除了C-反应蛋白和红细胞沉降率，大多数工作是检查细胞因子（特别是白细胞介素17和23），基质金属蛋白酶（MMP）标记物（特别是MMP 3）。为了评估放射学进展风险最高的患者，骨代谢、软骨和结缔组织降解产物以及脂肪因子的生物标志物已得到最广泛的评估。问题是，没有一种生物标志物可重复地显示出评估疾病活动或预测结果，这一领域仍然是一个未满足的需求，与行业利益相关者、监管机构、医疗保健系统、学术研究人员以及最终与患者和提供者相关。
With the growing awareness of the impact of chronic back pain and axial spondyloarthritis and recent breakthroughs in genetics and the development of novel treatments which may impact best on early disease, the need for markers that can facilitate early diagnosis and profiling those individuals at the highest risk for a bad outcome has never been greater. The genetic basis of ankylosing spondylitis has been considerably advanced, and HLA-B27 testing has a role in the diagnosis. Knowledge is still incomplete of the rest of the genetic contribution to disease susceptibility, and it is likely premature to use extensive genetic testing (other than HLA-B27) for diagnosis. Serum and plasma biomarkers have been examined extensively in assessing disease activity, treatment response, and as predictors or radiographic severity. For assessing disease activity, other than C-reactive protein and erythrocyte sedimentation rate, the most work has been in examining cytokines (particularly interleukin 17 and 23), matrix metalloproteinase (MMP) markers (particularly MMP3). For assessing those at the highest risk for radiographic progression, biomarkers of bony metabolism, cartilage and connective tissue degradation products, and adipokines have been most extensively assessed. The problem is that no individual biomarkers has been reproducibly shown to assess disease activity or predict outcome, and this area still remains an unmet need, of relevance to industry stakeholders, to regulatory bodies, to the healthcare system, to academic investigators, and finally to patients and providers.
登录
查看更多内容
影响因子：
--
作者：
Haroon, Nigil;Inman, Robert D.;Learch, Thomas J.;Weisman, Michael H.;Lee, MinJae;Rahbar, Mohammad H.;Ward, Michael M.;Reveille, John D.;Gensler, Lianne S.
通讯作者：
Gensler, Lianne S.
影响因子：
3.4
作者：
Chen, Chun-Hsiung;Chen, Hung-An;Chou, Chung-Tei
通讯作者：
Chou, Chung-Tei
影响因子：
4.6
作者：
Drouart, M;Saas, P;Toussirot, É
通讯作者：
Toussirot, É
影响因子：
3.7
作者：
Bay-Jensen, Anne C.;Wichuk, Stephanie;Maksymowych, Walter P.
通讯作者：
Maksymowych, Walter P.
影响因子：
27.4
作者：
FRANCK, H;KECK, E
通讯作者：
KECK, E